Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link



Dow Jones Industrial Average



) is trading down 17.0 points (-0.1%) at 16,484 as of Thursday, Apr 24, 2014, 10:36 a.m. ET. During this time, 107.5 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 417.7 million. The NYSE advances/declines ratio sits at 1,486 issues advancing vs. 1,361 declining with 230 unchanged.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Holding back the Dow today is




), which is lagging the broader Dow index with a 51-cent decline (-1.6%) bringing the stock to $30.41. This single loss is lowering the Dow Jones Industrial Average by 3.86 points or roughly accounting for 22.7% of the Dow's overall loss. Volume for Pfizer currently sits at 10.8 million shares traded vs. an average daily trading volume of 28.9 million shares.

Pfizer has a market cap of $198.2 billion and is part of the health care sector and drugs industry. Shares are up 0.9% year-to-date as of Wednesday's close. The stock's dividend yield sits at 3.3%.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products.

TheStreet Ratings rates Pfizer as a


. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more